Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Relea...
Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics
Our vision for a new type of cancer treatment is based on an implantable therapeutic system capable of ‘programmable’ on-demand delivery of drugs directly to the tumor. We conceive an implantable iontronic switch (bioSWITCH) to en...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TherACCage
Therapeutic Artificial Cells based on Molecular Cages for Gl...
181K€
Cerrado
PCIN-2016-093
NANOHILOS BIOACTIVOS ACTUADOS MAGNETICA Y FOTOQUIMICAMENTE P...
110K€
Cerrado
PID2020-113256RA-I00
SISTEMAS SUPRAMOLECULARES SENSIBLES A ESTIMULOS EXTERNOS PAR...
92K€
Cerrado
MBCTHERANOSTICSPION
Development and in vivo validation of a SPION based Theranos...
173K€
Cerrado
SAF2014-54057-R
DESARROLLO DE NANOMEDICINAS PARA TERAPIAS ANTITUMORALES E IN...
242K€
Cerrado
JCI-2008-3656
Development of delivery systems for the targeted and control...
101K€
Cerrado
Información proyecto bioSWITCH
Duración del proyecto: 38 meses
Fecha Inicio: 2022-12-20
Fecha Fin: 2026-02-28
Líder del proyecto
LINKOPINGS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Our vision for a new type of cancer treatment is based on an implantable therapeutic system capable of ‘programmable’ on-demand delivery of drugs directly to the tumor. We conceive an implantable iontronic switch (bioSWITCH) to enable a spatiotemporally controlled administration of highly potent chemotherapeutics, without the need for systemic administration of (pro)drugs or drug conjugates.
This radically new technology will be realized by a combination of next-level tools.
As a result, bioSWITCH can generate previously unobtainable discrete as well as continuous drug concentration profiles at the tumor site, and thus allows for the use of highly potent drugs that are otherwise not applicable due to high cytotoxicity.
The goal is to demonstrate the technology’s potential to effectively interfere with tumor progression using a xenograft pancreas cancer mouse model. Efficiently shrinking tumors in size allows for surgical resection of previously non-operable tumors and dramatically increases survival rates.
Our consortium of world leading academics and pioneering SMEs will ensure the translation of this disruptive technology into the market to maximize the socioeconomic impact.